SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals
REGN 725.28+3.0%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Miljenko Zuanic who wrote (2291)2/8/2018 9:36:37 PM
From: Miljenko Zuanic  Read Replies (1) of 3559
 
To continue on the same topic,
<We reaffirm our full year 2018 guidance for Sanofi reimbursement of Regeneron commercialization related expenses in 2018 to be in the range of $450 million and $500 million.>

So, they expect that Abs commercialization expense would be in (REGN 1/2 portion, reimbursed at~80%) 1.2 to 1.3B range, my question is will they make PROFIT in 2018? Would cumulative sale (for P + D + K) pass ~$1.4/1.5 B mark????

GOD BLESS, they were lucky with Eylea, to pay for all this "GREAT SCIENCE"!
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News